The price trend for Keros Therapeutics, Inc. (KROS) has been bearish lately and the stock has lost 5.8% over the past week.

Keros Therapeutics shareholder ADAR1 Capital Management said it plans to withhold votes for board members Mary Ann Gray and Alpna Seth. "ADAR1 calls for Keros to restructure the business, ...

Keros Therapeutics, Inc. (KROS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

Keros reported a net loss of $30.7 million in the second quarter of 2025 as compared to a net loss of $45.3 million in the second quarter of 2024. The decrease of $14.6 million was largely due to ...

LEXINGTON, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a ...

Keros Therapeutics, Inc.'s stock plummeted over 75% due to halting high-dose arms in its Phase 2 TROPOS trial for PAH, citing safety concerns. Despite the setback, Keros' partnership with Takeda ...

LEXINGTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and ...

Keros Therapeutics is considering whether it needs to find a buyer, while strengthening its stockholder rights as activist investors circle. The Lexington, Massachusetts-based biotech, which scrapped ...

Bank of America Securities analyst Jason Zemansky downgraded Keros Therapeutics, Inc. (NASDAQ:KROS) from Buy to Neutral, lowering the price forecast from $32 to $18. Zemansky noted that Keros has ...

Keros Therapeutics, Inc.‘s (NASDAQ:KROS) board of directors initiated a formal review process on Thursday to evaluate strategic alternatives, including a sale. “Consistent with our commitment to ...

LEXINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and ...

Positive news for Merck regarding a pulmonary hypertension drug helped Keros. Keros has enough cash, it says, to last through Q3 2024. Keros has three therapies in its pipeline to treat blood and ...